About us
Platform
Pipeline
Overview
Azelaprag (BGE-105)
BGE-100
Resources
Press releases
In the news
Events
Publications
Presentations
Podcast
Careers
Explore
Press releases
BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs
June 21, 2024
BioAge Labs Announces Inaugural Scientific Advisory Board to Support Advancement of Novel Therapeutics Targeting Metabolic Aging
May 16, 2024
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
April 9, 2024
BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
February 13, 2024
Show more
Home
About us
Platform
Pipeline
Overview
Azelaprag (BGE-105)
BGE-100
Resources
Press releases
In the news
Events
Publications
Presentations
Podcast
Careers